Consensus report from the 7th International Forum for Liver Magnetic Resonance Imaging.
- Merkle EM Clinic of Radiology and Nuclear Medicine, University Hospital Basel, Petersgraben 4, CH-4031, Basel, Switzerland. elmar.merkle@usb.ch.
- Zech CJ Clinic of Radiology and Nuclear Medicine, University Hospital Basel, Petersgraben 4, CH-4031, Basel, Switzerland.
- Bartolozzi C Department of Radiology, University of Pisa, Pisa, Italy.
- Bashir MR Department of Radiology, Duke University Medical Center, Durham, NC, USA.
- Ba-Ssalamah A Department of General and Pediatric Radiology, Medical University of Vienna, Vienna, Austria.
- Huppertz A Imaging Science Institute Charité, Berlin, Germany.
- Lee JM Department of Radiology, Seoul National University Hospital, Seoul, South Korea.
- Ricke J Department of Radiology and Nuclear Medicine, Otto-von-Guericke Universität Magdeburg, Magdeburg, Germany.
- Sakamoto M Department of Pathology, Keio University School of Medicine, Tokyo, Japan.
- Sirlin CB Liver Imaging Group, Department of Radiology, University of California, San Diego, California, USA.
- Ye SL Department of Hepatic Oncology, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.
- Zeng M Radiologic Diagnostic Department, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.
- 2015-06-14
Published in:
- European radiology. - 2016
Gadoxetic acid
Hepatocellular carcinoma
Liver function tests
Liver neoplasms
Magnetic resonance imaging
Adenoma, Liver Cell
Carcinoma, Hepatocellular
Cholangiocarcinoma
Contrast Media
Diagnosis, Differential
Focal Nodular Hyperplasia
Gadolinium DTPA
Humans
Liver Neoplasms
Magnetic Resonance Imaging
Precancerous Conditions
English
OBJECTIVES
Liver-specific MRI is a fast-growing field, with technological and protocol advancements providing more robust imaging and allowing a greater depth of information per examination. This article reports the evidence for, and expert thinking on, current challenges in liver-specific MRI, as discussed at the 7th International Forum for Liver MRI, which was held in Shanghai, China, in October 2013.
METHODS
Topics discussed included the role of gadoxetic acid-enhanced MRI in the differentiation of focal nodular hyperplasia from hepatocellular adenoma and small hepatocellular carcinoma (HCC) from small intrahepatic cholangiocarcinoma (in patients with chronic liver disease), the differentiation of low-grade dysplastic nodule (DN) from pre-malignant high-grade DN and early HCC, and treatment planning and assessment of treatment response for patients with HCC and colorectal liver metastasis. Optimization of the gadoxetic acid-enhanced MRI protocol to gain robust arterial and hepatobiliary phase images was also discussed.
RESULTS AND CONCLUSIONS
Gadoxetic acid-enhanced MRI demonstrates added value for the detection and characterization of focal liver lesions and shows promise in a number of new indications, including regional liver functional assessment and patient monitoring after therapy; however, more data are needed in some areas, and further developments are needed to translate cutting-edge techniques into clinical practice.
KEY POINTS
Liver-specific MRI is a fast-growing field, with many technological and protocol advancements. Gadoxetic acid-enhanced MRI demonstrates value for detecting and characterizing focal liver lesions. Gadoxetic acid-enhanced MRI shows promise in regional functional assessment and patient monitoring. Further developments are needed to translate cutting-edge techniques into clinical practice.
Liver-specific MRI is a fast-growing field, with technological and protocol advancements providing more robust imaging and allowing a greater depth of information per examination. This article reports the evidence for, and expert thinking on, current challenges in liver-specific MRI, as discussed at the 7th International Forum for Liver MRI, which was held in Shanghai, China, in October 2013.
METHODS
Topics discussed included the role of gadoxetic acid-enhanced MRI in the differentiation of focal nodular hyperplasia from hepatocellular adenoma and small hepatocellular carcinoma (HCC) from small intrahepatic cholangiocarcinoma (in patients with chronic liver disease), the differentiation of low-grade dysplastic nodule (DN) from pre-malignant high-grade DN and early HCC, and treatment planning and assessment of treatment response for patients with HCC and colorectal liver metastasis. Optimization of the gadoxetic acid-enhanced MRI protocol to gain robust arterial and hepatobiliary phase images was also discussed.
RESULTS AND CONCLUSIONS
Gadoxetic acid-enhanced MRI demonstrates added value for the detection and characterization of focal liver lesions and shows promise in a number of new indications, including regional liver functional assessment and patient monitoring after therapy; however, more data are needed in some areas, and further developments are needed to translate cutting-edge techniques into clinical practice.
KEY POINTS
Liver-specific MRI is a fast-growing field, with many technological and protocol advancements. Gadoxetic acid-enhanced MRI demonstrates value for detecting and characterizing focal liver lesions. Gadoxetic acid-enhanced MRI shows promise in regional functional assessment and patient monitoring. Further developments are needed to translate cutting-edge techniques into clinical practice.
- Language
-
- English
- Open access status
- hybrid
- Identifiers
-
- DOI 10.1007/s00330-015-3873-2
- PMID 26070500
- Persistent URL
- https://sonar.ch/global/documents/232434
Statistics
Document views: 56
File downloads:
- Full-text: 0